- Global Pharma News & Resources

Cancer Supportive Care Drugs Market 2016-2018 & 2022: Analysis & Forecast by Therapeutic Class, Major Markets, Vendor Landscape, and Segment Forecasts -

The "Cancer Supportive Care Drugs Market Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Major Markets, Vendor Landscape, And Segment Forecasts, 2016 - 2022" report has been added to's offering.

The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by 2022, progressing at a CAGR of 1.8% during the forecast period.

The market is anticipated to be driven by large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments.

Chemotherapy and radiotherapy are traditional methods for cancer treatment with approximately four million people receiving chemotherapy every year. Supportive care products are essential to prevent and manage symptoms and side-effects of cancer and its treatment. Among major cancer types, lung and breast cancers are the most prominent cancer type with the highest demand for supportive care drugs.

G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Cancer supportive care drugs market Overview

Chapter 5 Global Cancer Supportive Care Pipeline Intelligence

Chapter 6 Company Profiles

  • Amgen
  • Merck
  • Helsinn Healthcare
  • Johnson & Johnson
  • Heron Pharma
  • Roche
  • Novartis (Sandoz)
  • Tesaro

For more information about this report visit

View source version on

Editor Details

Last Updated: 01-Nov-2018